Carna Biosciences, Inc. (TYO:4572)
Japan · Delayed Price · Currency is JPY 304.00
-2.00 (-0.65%)
Aug 6, 2026, 1:55 PM JST
Carna Biosciences Balance Sheet
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 1,483 | 516 | 2,108 | 2,889 | 3,379 | 3,817 |
Cash & Short-Term Investments | 1,483 | 516 | 2,108 | 2,889 | 3,379 | 3,817 |
Cash Growth | -3.00% | -75.52% | -27.03% | -14.50% | -11.47% | -11.21% |
Receivables | 117.57 | 100 | 87 | 788 | 182 | 1,243 |
Inventory | 155.36 | 154 | 154 | 140 | 118 | 110 |
Prepaid Expenses | 51.76 | 66 | - | - | - | - |
Other Current Assets | 352.03 | 339 | 388 | 374 | 425 | 148 |
Total Current Assets | 2,160 | 1,175 | 2,737 | 4,191 | 4,104 | 5,318 |
Property, Plant & Equipment | - | - | - | 105 | 100 | 51 |
Long-Term Investments | 53.63 | 54 | 34 | 51 | 59 | 59 |
Other Intangible Assets | - | - | - | 1 | 1 | 2 |
Other Long-Term Assets | - | - | 1 | 1 | 2 | 2 |
Total Assets | 2,214 | 1,229 | 2,772 | 4,349 | 4,266 | 5,432 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | - | - | 2 | 1 | 1 | 2 |
Current Portion of Long-Term Debt | 3.41 | 8 | 19 | 120 | 151 | 239 |
Current Portion of Leases | 8.59 | 8 | 8 | 6 | - | - |
Current Income Taxes Payable | 6.18 | 140 | 180 | 218 | 265 | 332 |
Current Unearned Revenue | - | - | - | - | - | 177 |
Other Current Liabilities | 116.17 | 12 | 13 | 30 | 19 | 24 |
Total Current Liabilities | 134.35 | 168 | 222 | 375 | 436 | 774 |
Long-Term Debt | 2,174 | 681 | 8 | 28 | 148 | 300 |
Long-Term Leases | 14.15 | 16 | 24 | 28 | - | - |
Other Long-Term Liabilities | 54.89 | 56 | 44 | 42 | 42 | 45 |
Total Liabilities | 2,377 | 921 | 298 | 473 | 626 | 1,119 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 24.85 | 14 | 2,447 | 2,076 | 1,382 | 1,056 |
Additional Paid-In Capital | 2,207 | 2,196 | 6,198 | 5,827 | 5,133 | 4,808 |
Retained Earnings | -2,494 | -1,980 | -6,253 | -4,075 | -2,922 | -1,572 |
Comprehensive Income & Other | 99.03 | 78 | 82 | 48 | 47 | 21 |
Shareholders' Equity | -163.55 | 308 | 2,474 | 3,876 | 3,640 | 4,313 |
Total Liabilities & Equity | 2,214 | 1,229 | 2,772 | 4,349 | 4,266 | 5,432 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2,200 | 713 | 59 | 182 | 299 | 539 |
Net Cash (Debt) | -716.65 | -197 | 2,049 | 2,707 | 3,080 | 3,278 |
Net Cash Growth | - | - | -24.31% | -12.11% | -6.04% | -15.32% |
Net Cash Per Share | -37.47 | -10.31 | 114.41 | 161.13 | 226.18 | 258.20 |
Filing Date Shares Outstanding | 19.19 | 19.19 | 19.1 | 17.14 | 16.34 | 13.48 |
Total Common Shares Outstanding | 19.19 | 19.14 | 19.1 | 17.14 | 14.21 | 13.31 |
Working Capital | 2,026 | 1,007 | 2,515 | 3,816 | 3,668 | 4,544 |
Book Value Per Share | -8.52 | 16.09 | 129.55 | 226.07 | 256.14 | 324.08 |
Tangible Book Value | -163.55 | 308 | 2,474 | 3,875 | 3,639 | 4,311 |
Tangible Book Value Per Share | -8.52 | 16.09 | 129.55 | 226.02 | 256.07 | 323.93 |
Order Backlog | - | 23.01 | 13.09 | 39.76 | 58.12 | 257.29 |